140 Chapter 6 17 Sacco S, Merki-Feld GS, Ægidius KL et al. Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). The Journal of Headache and Pain 2018; 19 (1): 76. 18 De Leo V, Scolaro V, Musacchio MC et al. Combined oral contraceptives in women with menstrual migraine without aura. Fertil Steril 2011; 96 (4): 917-920. 19 Coffee AL, Sulak PJ, Hill AJ et al. Extended cycle combined oral contraceptives and prophylactic frovatriptan during the hormone-free interval in women with menstrualrelated migraines. J Womens Health (Larchmt) 2014; 23 (4): 310-317. 20 Sulak P, Willis S, Kuehl T et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. Headache 2007; 47 (1): 27-37. 21 Ziaei S, Kazemnejad A, Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. Med Sci Monit 2009; 15 (1): Cr16-19. 22 Bousser MG, Welch KM. Relation between migraine and stroke. Lancet Neurol 2005; 4 (9): 533-542. 23 Kurth T, Slomke MA, Kase CS et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005; 64 (6): 1020-1026. 24 van der Arend BWH, Verhagen IE, van Leeuwen M et al. Defining migraine days, based on longitudinal E-diary data. Cephalalgia 2023; 43 (5). 25 Verhagen IE, Spaink HAJ, van der Arend BWH et al. Validation of diagnostic ICHD-3 criteria for menstrual migraine. Cephalalgia 2022; 42 (11-12): 1184-1193. 26 Van Casteren DS, Verhagen IE, De Boer I et al. E-diary use in clinical headache practice: A prospective observational study. Cephalalgia 2021; 41 (11-12): 1161-1171. 27 Olesen J. International Classification of Headache Disorders. The Lancet Neurology 2018; 17 (5): 396-397. 28 Castor EDC. Castor Electronic Data Capture. 2019. 29 Younger J, Gandhi V, Hubbard E et al. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials 2012; 9 (6): 767-776. 30 van Casteren DS, Verhagen IE, Onderwater GL et al. Sex differences in prevalence of migraine trigger factors: A cross-sectional study. Cephalalgia 2021; 41 (6): 643-648. 31 van Casteren DS, Verhagen IE, van der Arend BWH et al. Comparing Perimenstrual and Nonperimenstrual Migraine Attacks Using an e-Diary. Neurology 2021; 97 (17): e1661-e1671.
RkJQdWJsaXNoZXIy MjY0ODMw